{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T11:49:51Z","timestamp":1719316191894},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100009331","name":"Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support","doi-asserted-by":"crossref","award":["ZY201402"],"award-info":[{"award-number":["ZY201402"]}],"id":[{"id":"10.13039\/501100009331","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100010270","name":"The Capital Health Research and Development of Special","doi-asserted-by":"crossref","award":["2011-2017-02"],"award-info":[{"award-number":["2011-2017-02"]}],"id":[{"id":"10.13039\/501100010270","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Clin Microbiol Antimicrob"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12941-016-0138-0","type":"journal-article","created":{"date-parts":[[2016,4,14]],"date-time":"2016-04-14T16:05:41Z","timestamp":1460649941000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["De novo entecavir+adefovir dipivoxil+lamivudine triple-resistance mutations resulting from sequential therapy with adefovir dipivoxil, and lamivudine"],"prefix":"10.1186","volume":"15","author":[{"given":"Song","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huichun","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,4,14]]},"reference":[{"issue":"Suppl 1","key":"138_CR1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/jgh.12220","volume":"28","author":"Y Cui","year":"2013","unstructured":"Cui Y, Jia J. Update on epidemiology of hepatitis B and C in China. J Gastroenterol Hepatol. 2013;28(Suppl 1):7\u201310.","journal-title":"J Gastroenterol Hepatol"},{"key":"138_CR2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","volume":"57","author":"EASL clinical practice guidelines","year":"2012","unstructured":"EASL clinical practice guidelines. Management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167\u201385.","journal-title":"J Hepatol"},{"key":"138_CR3","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2009.08.063","volume":"137","author":"F Zoulim","year":"2009","unstructured":"Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology. 2009;137:1593\u2013608.","journal-title":"Gastroenterology"},{"key":"138_CR4","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/hep.21290","volume":"44","author":"HJ Yim","year":"2006","unstructured":"Yim HJ, Hussain M, Liu Y, Wong SN, Fung SK, Lok AS. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology. 2006;44:703\u201312.","journal-title":"Hepatology"},{"key":"138_CR5","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.3851\/IMP1679","volume":"15","author":"Y Liu","year":"2010","unstructured":"Liu Y, Wang C, Zhong Y, Chen L, Li X, Ji D, et al. Evolution and suppression of HBV strains with multidrug resistance to lamivudine, adefovir dipivoxil and entecavir in a patient with chronic hepatitis B. Antivir Ther. 2010;15:1185\u201390.","journal-title":"Antivir Ther"},{"key":"138_CR6","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jmv.23440","volume":"85","author":"SS Kim","year":"2013","unstructured":"Kim SS, Cho SW, Kim SO, Hong SP, Cheong JY. Multidrug-resistant hepatitis B virus resulting from sequential monotherapy with lamivudine, adefovir, and entecavir: clonal evolution during lamivudine plus adefovir therapy. J Med Virol. 2013;85:55\u201364.","journal-title":"J Med Virol"},{"key":"138_CR7","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1177\/135965350501000507","volume":"10","author":"H Yang","year":"2005","unstructured":"Yang H, Qi X, Sabogal A, Miller M, Xiong S, Delaney WE. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther. 2005;10:625\u201333.","journal-title":"Antivir Ther."},{"key":"138_CR8","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1365-2893.2010.01301.x","volume":"18","author":"J Inoue","year":"2011","unstructured":"Inoue J, Ueno Y, Wakui Y, Niitsuma H, Fukushima K, Yamagiwa Y, et al. Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern. J Viral Hepat. 2011;18:206\u201315.","journal-title":"J Viral Hepat"},{"key":"138_CR9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3350\/cmh.2013.19.1.29","volume":"19","author":"MS Park","year":"2013","unstructured":"Park MS, Kim BK, Kim KS, Kim JK, Kim SU, Park JY, et al. Antiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B. Clin Mol Hepatol. 2013;19:29\u201335.","journal-title":"Clin Mol Hepatol"},{"key":"138_CR10","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1111\/liv.12845","volume":"35","author":"YE Chon","year":"2015","unstructured":"Chon YE, Jin B, Ahn SH, Kim S, Kim ND, Park JH, et al. Clonal evolution of multidrug resistant hepatitis B virus during entecavir rescue therapy. Liver Int. 2015;35:2370\u201383.","journal-title":"Liver Int"},{"key":"138_CR11","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/1743-422X-10-162","volume":"10","author":"XH Xu","year":"2013","unstructured":"Xu XH, Li GL, Qin Y, Li Q, He FQ, Li JY, et al. Entecavir plus adefovir rescue therapy for chronic hepatitis B patients after multiple treatment failures in real-life practice. Virol J. 2013;10:162.","journal-title":"Virol J"},{"key":"138_CR12","first-page":"358","volume":"11","author":"J Yan","year":"2011","unstructured":"Yan J, Xie W, Wang Q, Li Y, Feng X, Cheng J. The optimal threshold: baseline serum hepatitis B virus DNA and alanine transaminase levels can predict the 2-year on-treatment virological response to lamivudine. Hepat Mon. 2011;11:358\u201363.","journal-title":"Hepat Mon"},{"key":"138_CR13","doi-asserted-by":"crossref","first-page":"W654","DOI":"10.1093\/nar\/gkh419","volume":"32","author":"M Rozanov","year":"2004","unstructured":"Rozanov M, Plikat U, Chappey C, Kochergin A, Tatusova T. A web-based genotyping resource for viral sequences. Nucleic Acids Res. 2004;32:W654\u20139.","journal-title":"Nucleic Acids Res"},{"key":"138_CR14","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jhep.2010.03.020","volume":"53","author":"NY Heo","year":"2010","unstructured":"Heo NY, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. J Hepatol. 2010;53:449\u201354.","journal-title":"J Hepatol"},{"key":"138_CR15","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1128\/AAC.00338-12","volume":"56","author":"YS Lim","year":"2012","unstructured":"Lim YS, Lee JY, Lee D, Shim JH, Lee HC, Lee YS, et al. Randomized trial of entecavir plus adefovir in patients with lamivudine-resistant chronic hepatitis B who show suboptimal response to lamivudine plus adefovir. Antimicrob Agents Chemother. 2012;56:2941\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"138_CR16","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","volume":"359","author":"P Marcellin","year":"2008","unstructured":"Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359:2442\u201355.","journal-title":"N Engl J Med"},{"key":"138_CR17","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa051287","volume":"354","author":"CL Lai","year":"2006","unstructured":"Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354:1011\u201320.","journal-title":"N Engl J Med"},{"key":"138_CR18","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/hep.21698","volume":"46","author":"AS Lok","year":"2007","unstructured":"Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology. 2007;46:254\u201365.","journal-title":"Hepatology"},{"key":"138_CR19","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1128\/AAC.00970-09","volume":"54","author":"HG Niesters","year":"2010","unstructured":"Niesters HG, Zoulim F, Pichoud C, Buti M, Shapiro F, D\u2019Heuvaert N, et al. Validation of the INNO-LiPA HBV DR assay (version 2) in monitoring hepatitis B virus-infected patients receiving nucleoside analog treatment. Antimicrob Agents Chemother. 2010;54:1283\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"138_CR20","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1177\/135965350501000306","volume":"10","author":"HS Kim","year":"2005","unstructured":"Kim HS, Han KH, Ahn SH, Kim EO, Chang HY, Moon MS, et al. Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization. Antivir Ther. 2005;10:441\u20139.","journal-title":"Antivir Ther"},{"key":"138_CR21","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s12072-012-9411-2","volume":"7","author":"W Li","year":"2013","unstructured":"Li W, Warner N, Sozzi V, Yuen L, Colledge D, Li T, et al. Hepatitis B virus genotype C encoding resistance mutations that emerge during adefovir dipivoxil therapy: in vitro replication phenotype. Hepatol Int. 2013;7:443\u201350.","journal-title":"Hepatol Int"},{"key":"138_CR22","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1128\/JCM.01518-10","volume":"48","author":"X Li","year":"2010","unstructured":"Li X, Wang L, Zhong Y, Wong VW, Xu Z, Liu Y, et al. Hepatitis B virus (HBV) subgenotypes C2 and B2 differ in lamivudine- and adefovir-resistance-associated mutational patterns in HBV-infected Chinese patients. J Clin Microbiol. 2010;48:4363\u20139.","journal-title":"J Clin Microbiol"},{"key":"138_CR23","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/hep.22295","volume":"48","author":"N Warner","year":"2008","unstructured":"Warner N, Locarnini S. The antiviral drug selected hepatitis B virus rtA181T\/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology. 2008;48:88\u201398.","journal-title":"Hepatology"},{"key":"138_CR24","doi-asserted-by":"crossref","first-page":"6805","DOI":"10.1128\/JVI.00635-14","volume":"88","author":"SH Ahn","year":"2014","unstructured":"Ahn SH, Park YK, Park ES, Kim JH, Kim DH, Lim KH, et al. The impact of the hepatitis B virus polymerase rtA181T mutation on replication and drug resistance is potentially affected by overlapping changes in surface gene. J Virol. 2014;88:6805\u201318.","journal-title":"J Virol"}],"container-title":["Annals of Clinical Microbiology and Antimicrobials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-016-0138-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T21:16:22Z","timestamp":1655500582000},"score":1,"resource":{"primary":{"URL":"http:\/\/ann-clinmicrob.biomedcentral.com\/articles\/10.1186\/s12941-016-0138-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,14]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["138"],"URL":"https:\/\/doi.org\/10.1186\/s12941-016-0138-0","relation":{},"ISSN":["1476-0711"],"issn-type":[{"value":"1476-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,14]]},"article-number":"24"}}